Announcement of the Launch of “SALAGEN® Granules 0.5%” for the Treatment of Dry Mouth Symptoms

The Company's Official Page
http://www.kissei.co.jp/e_contents/relation/l4/Vcms4_00000842.html
Back To Previous Page

December 12, 2014 Announcement of the Launch of “SALAGEN® Granules 0.5%” for the Treatment of Dry Mouth Symptoms

Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical Co., Ltd. [Head Office: Matsumoto-city, Nagano, Japan; Chairman and CEO: Mutsuo Kanzawa (“Kissei”)] announced today the launch of “SALAGEN® Granules 0.5%,” a new formulation of “SALAGEN®” (generic name: pilocarpine hydrochloride) for the treatment of symptoms of dry mouth.

Since 2005, “SALAGEN® Tab.” has been marketed for the indication of “improvement of dry mouth symptoms associated with radiotherapy to the head and neck”


Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

    この内容でのリリース掲載はまだ無いか、集計されておりません。

Most Popular: Pharmaceuticals

1. Kaken and Sunstar to sign a License Agre...
Kaken Pharmaceutical Co.,Ltd. 2007/06/19
2. Kaken Pharmaceutical and Taiyo Yakuhin E...
Kaken Pharmaceutical Co.,Ltd. 2004/04/27
3. 7th Journal of Pharmaceutical Science an...
Kaken Pharmaceutical Co.,Ltd. 2003/04/10
4. Pharmacia and KAKEN Revise Copromotion A...
Kaken Pharmaceutical Co.,Ltd. 2001/12/17
5. Launching of ゛MIROL Ophth. Soln. 0.5%&qu...
Kaken Pharmaceutical Co.,Ltd. 2001/02/21

Latest News: Kissei Pharmaceutical Co., Ltd.


Most Popular: Kissei Pharmaceutical Co., Ltd.

1. Approval of an Additional Indication of ...
2009/02/24

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

Home

Terms & Conditions

TwitterFacebook

About Us